Cemiplimab on the Path to EU Approval for Adjuvant CSCC Treatment
Introduction to Libtayo and Its Significance
Understanding Cutaneous Squamous Cell Carcinoma (CSCC)
Libtayo’s Role in CSCC Treatment
FDA and CHMP Approvals: A New Era
Impact on High-Risk CSCC Patients
Future Implications for Cancer Immunotherapy
Concluding Thoughts on Libtayo’s Approval